Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome.
This case highlights the importance of genetic testing for Lynch syndrome and suggests a potential association with pancreatic neuroendocrine tumors, but further studies are needed to confirm these findings.
Where it sits
this study against the rest of the vipivotide corpusSummary and findings
This case discusses a woman with Lynch syndrome who developed a non-functioning pancreatic neuroendocrine tumor after primary colon adenocarcinoma. Following surgical excision of the pancreatic mass, multiple liver lesions were discovered 6 months later and were treated with octreotide and Lutetium-177 vipivotide tetraxetan. The patient is reported to be in remission and undergoes monitoring every 6 months.
Abstract
Lynch syndrome (LS), a well-known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non-functioning pancreatic neuroendocrine tumor (P-NET) following primary colon adenocarcinoma. Multiple liver lesions were discovered 6 months following surgical excision the pancreatic mass and were later determined to be a neuroendocrine tumor. Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan. She is in remission and takes positron emission tomography scans every 6 months for monitoring. This case highlights the importance of LS genetic testing, the function of microsatellite instability (MSI) as a screening marker, and the need for additional study on the relationship between LS and P-NETs, particularly through advanced molecular testing to confirm lesion relationships. The role of microsatellite instability (MSI) as a screening marker, and personalized treatment approaches like immunotherapy for dMMR tumors. Understanding these correlations may assist in early discovery, surveillance, and customized treatment for patients dealing with LS-associated malignancies.
Background
This paper addresses the relationship between Lynch syndrome and the development of pancreatic neuroendocrine tumors (P-NETs). Lynch syndrome is known to increase the risk of various cancers, particularly colorectal cancer. The significance of this case lies in its exploration of a rare manifestation of LS and the potential implications for genetic testing and personalized treatment strategies.
Methods
This is a case report detailing the clinical course of a single patient with Lynch syndrome who developed a non-functioning P-NET. The patient underwent surgical excision of the pancreatic mass, followed by treatment with octreotide and Lutetium-177 vipivotide tetraxetan. Monitoring was conducted via positron emission tomography scans every 6 months.
Results
The patient developed multiple liver lesions 6 months after the surgical excision of the pancreatic mass. These lesions were treated with octreotide and Lutetium-177 vipivotide tetraxetan, leading to observed shrinkage. Specific numeric data regarding the extent of shrinkage or other quantitative measures were not reported.
Interpretation
The findings suggest a potential link between Lynch syndrome and the development of P-NETs, although this is based on a single case. The treatment outcomes, while positive, do not provide sufficient evidence to establish a causal relationship or generalize to a broader population. The lack of a control group and reliance on a single patient's experience limits the conclusions that can be drawn.
Key findings
- Multiple liver lesions discovered 6 months following surgical excision.
- Liver lesions shrank after treatment with octreotide and Lutetium-177 vipivotide tetraxetan.
- Patient is in remission and takes positron emission tomography scans every 6 months for monitoring.
Limitations
- Case report, not a controlled study.
- Single patient experience limits generalizability.
- No quantitative treatment outcome data reported.